Drug Metabolism and Drug Interactions最新文献_第8页

Human cytochrome P450 4F3: structure, functions, and prospects. 人细胞色素P450 4F3:结构、功能及前景。

Drug Metabolism and Drug Interactions Pub Date : 2012-04-19 DOI: 10.1515/dmdi-2011-0037

Laurent Corcos, Danièle Lucas, Catherine Le Jossic-Corcos, Yvonne Dréano, Brigitte Simon, Emmanuelle Plée-Gautier, Yolande Amet, Jean-Pierre Salaün

{"title":"Human cytochrome P450 4F3: structure, functions, and prospects.","authors":"Laurent Corcos, Danièle Lucas, Catherine Le Jossic-Corcos, Yvonne Dréano, Brigitte Simon, Emmanuelle Plée-Gautier, Yolande Amet, Jean-Pierre Salaün","doi":"10.1515/dmdi-2011-0037","DOIUrl":"https://doi.org/10.1515/dmdi-2011-0037","url":null,"abstract":"Cytochrome P450 4F3 (CYP4F3), originally identified as one of the leukotriene B4 ω-hydroxylases, belongs to a CYP gene family that comprises several members, which participate in the metabolism of various endobiotics, as well as some xenobiotics. The CYP4F gene family is clustered in a 0.5-Mb stretch of genomic DNA on the p13 region of chromosome 19. Apart from the ω-hydroxylation of leukotriene B4 and prostaglandins, CYP4F3 is the main catalyst in the oxidation of fatty acid epoxides. CYP4F3 expression results from the synthesis of two distinct enzymes, CYP4F3A and CYP4F3B, which originate from the alternative splicing of a single pre-mRNA precursor molecule. Remarkably, the selection of either isoform is part of a tissue-specific control through which CYP3F3A is mostly expressed in leukocytes and CYP4F3B mostly in the liver. Recently, CYP4F3 single nucleotide polymorphisms have been incriminated in the onset of pathologies, including celiac or Crohn's diseases. Although much has been discovered in the regulation and function of CYP4F2, the closest CYP4F subfamily member, analyses of CYP4F3 enzymes lag somewhat behind in the field of our knowledge. In this short review, emphasis will be placed on the regulation and the functional roles of human CYP4F3.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 2","pages":"63-71"},"PeriodicalIF":0.0,"publicationDate":"2012-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2011-0037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30696725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cytochrome P450 enzymes. 丹参与中药相互作用:细胞色素P450酶的作用研究进展。

Drug Metabolism and Drug Interactions Pub Date : 2012-03-02 DOI: 10.1515/dmdi-2011-0038

Xuelin Zhou, Kelvin Chan, John H K Yeung

{"title":"Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cytochrome P450 enzymes.","authors":"Xuelin Zhou, Kelvin Chan, John H K Yeung","doi":"10.1515/dmdi-2011-0038","DOIUrl":"https://doi.org/10.1515/dmdi-2011-0038","url":null,"abstract":"Danshen, the dried root and rhizome of Salvia miltiorrhiza Bunge, is a widely used medicinal plant for the treatment of cardiovascular diseases in China and a complementary medicine in the West. Danshen is indexed in the 2010 Chinese Pharmacopoeia, with more than 35 formulations and concoctions containing Danshen water-extracts, ethanolic extracts or their combination, which are rich in phenolic acids and different levels of tanshinones. There are rare reports on the adverse effects of Danshen preparations. It is, however, well-known that Danshen leads the anticoagulation failure of warfarin. The Danshen-warfarin interaction may be mediated via both pharmacodynamic and pharmacokinetic mechanisms. This review does not summarize recent progress, but the effects of Danshen and its active ingredients on the interactions of cytochrome P450 (CYP450) and drug transporters, as well as the analysis of ingredients, and the metabolism and pharmacokinetics that are related to these interactions. Tanshinones play significant roles in the inhibition and induction of several CYP450 isozymes. It can be concluded that precautions should be taken when using Danshen preparations rich in tanshinones for CYP-related herb-drug interactions.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 1","pages":"9-18"},"PeriodicalIF":0.0,"publicationDate":"2012-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2011-0038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30705730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 53

Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. 在药物基因组学时代，选择性血清素再摄取抑制剂与其他常用处方药的药代动力学相互作用。

Drug Metabolism and Drug Interactions Pub Date : 2012-02-29 DOI: 10.1515/dmdi-2011-0033

Vangelis G Manolopoulos, Georgia Ragia, Georgios Alevizopoulos

引用次数: 17

The microstructure of DNA-egg yolk phosphatidylcholine-gemini surfactants complexes: effect of the spacer length. dna -卵黄磷脂酰胆碱-gemini表面活性剂复合物的微观结构:间隔长度的影响。

Drug Metabolism and Drug Interactions Pub Date : 2012-02-14 DOI: 10.1515/dmdi-2011-0034

Daniela Uhríková, Petra Pullmannová, Adriana Sabíková, Ferdinand Devínsky, Sergio S Funari

{"title":"The microstructure of DNA-egg yolk phosphatidylcholine-gemini surfactants complexes: effect of the spacer length.","authors":"Daniela Uhríková, Petra Pullmannová, Adriana Sabíková, Ferdinand Devínsky, Sergio S Funari","doi":"10.1515/dmdi-2011-0034","DOIUrl":"https://doi.org/10.1515/dmdi-2011-0034","url":null,"abstract":"Background: The length of spacer of gemini surfactants affects the DNA packing in DNA-neutral phospholipid-gemini surfactant complexes.Methods: The microstructure of complexes DNA-egg yolk phosphatidylcholine (EYPC)-alkane-α,ω-diyl-bis(dodecylxaddimethylammonium bromides) (CnGS, spacer n=2-12, n is even) was studied using small angle X-ray diffraction.Results: At EYPC:CnGS=1:1 mol/mol, the condensed lamellar phase was identified in complexes with CnGS, n=2-4, whereas longer spacer (n≥6) induced a hexagonal phase. The condensed lamellar phase Lαc was observed in the range 2≤ EYPC:GnGS≤10 (mol/mol) in all complexes. The distance between adjacent DNA strands increases linearly with decreasing surface charge density of EYPC-CnGS vesicles. We determined the increase in dDNA 0.40±0.03 nm/1 mol of EYPC from the slope of dDNA=f (molEYPC/molCnGS) in the range of molar ratios 2≤EYPC:CnGS≤5. At lower surface charge density, EYPC:CnGS>5 mol/mol, the length of CnGS spacer (n=6-10) modulates the DNA-DNA distance.Conclusions: Both the short spacer of CnGS and the low molar ratio EYPC:CnGS result in the closest DNA-DNA packing. A high surface charge density of membrane was reported as a key parameter for transfection efficiency of Lαc phase-forming complexes.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 1","pages":"47-54"},"PeriodicalIF":0.0,"publicationDate":"2012-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2011-0034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30705734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The aryl hydrocarbon receptor system. 芳烃受体体系。

Drug Metabolism and Drug Interactions Pub Date : 2012-01-31 DOI: 10.1515/dmdi-2011-0035

Robert Barouki, Martine Aggerbeck, Lawrence Aggerbeck, Xavier Coumoul

{"title":"The aryl hydrocarbon receptor system.","authors":"Robert Barouki, Martine Aggerbeck, Lawrence Aggerbeck, Xavier Coumoul","doi":"10.1515/dmdi-2011-0035","DOIUrl":"https://doi.org/10.1515/dmdi-2011-0035","url":null,"abstract":"The aryl hydrocarbon receptor (AhR) recognizes a large number of xenobiotics, such as polyaromatic hydrocarbons (PAHs) and dioxins, and it activates several metabolic and detoxification pathways. Recent evidence suggests that this receptor also has important endogenous functions subsequent to activation by natural dietary compounds and/or endogenous metabolites. This receptor, thus, has physiological functions that extend beyond specific instances of detoxification. Understanding the roles played by this receptor might be enhanced by a systems biology approach. Indeed, the AhR \"ligandome\" is very complex and the different classes of ligands involved could induce widely diverse effects. The protein \"interactome\" of the AhR comprises several tens of proteins and it is altered by the binding of ligands to the receptor. Furthermore, large-scale studies have shown cell and tissue-specific patterns of regulated gene expression which may depend upon the type of ligand, although these aspects need further substantiation. Finally, the AhR biological effects are extensive and include detoxification, cellular proliferation and migration, immune regulation and neuronal effects. A holistic approach should provide a better understanding of the biology of this receptor in addition to providing new avenues for the identification of specific toxicity mechanisms.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 1","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2012-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2011-0035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30705729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 112

Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects. CYP2D6*10、CYP3A5*3、CYP1A2*1F和ABCB1 C3435T多态性对氟氯胺在中国健康人体内药代动力学的影响

Drug Metabolism and Drug Interactions Pub Date : 2012-01-09 DOI: 10.1515/dmdi-2011-0032

Miao Hu, Ya-Ling Yang, Benny S P Fok, Sze-Wa Chan, Tanya T W Chu, Emily W M Poon, Ophelia Q P Yin, Vincent H L Lee, Brian Tomlinson

{"title":"Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.","authors":"Miao Hu, Ya-Ling Yang, Benny S P Fok, Sze-Wa Chan, Tanya T W Chu, Emily W M Poon, Ophelia Q P Yin, Vincent H L Lee, Brian Tomlinson","doi":"10.1515/dmdi-2011-0032","DOIUrl":"https://doi.org/10.1515/dmdi-2011-0032","url":null,"abstract":"Background: Although flecainide is thought to be meta-bolized predominantly by cytochrome P450 (CYP) 2D6, it shows pharmacokinetic interactions with drugs, such as verapamil and digoxin, which may suggest other CYP pathways or ATP-binding cassette (ABC) transporters might be involved. This study evaluated effects of common polymorphisms in Chinese in CYP2D6, CYP3A5, CYP1A2, and ABCB1 on flecainide pharmacokinetics.Methods: Single oral 100-mg doses of flecainide were given to 15 healthy male Chinese subjects who were genotyped for the CYP2D6*2, *5, *10, CYP3A5*3, CYP1A2*1F and ABCB1 C1236T, G2677T/A, and C3435T polymorphisms.Results: There was no significant difference in the pharmacokinetics of flecainide among CYP2D6 (mainly involving *10) genotypes. The CYP3A5*3/*3 subjects (n=8) had a 26% higher systemic exposure (AUC0-∞) and 17% lower apparent oral clearance of flecainide than the combined group of CYP3A5*1/*1 (n=6) and CYP3A5*1/*3 (n=1) subjects (p<0.05). Subjects homozygous for CYP1A2*1F tended to have lower systemic exposure and increased clearance of flecainide compared to those with CYP1A2*1A/1F in subjects with at least one CYP2D6 variant allele.Conclusions: The disposition of flecainide appeared to be influenced by the CYP3A5*3 and possibly the CYP1A2*1F polymorphisms, particularly in subjects with CYP2D6 variant alleles.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 1","pages":"33-9"},"PeriodicalIF":0.0,"publicationDate":"2012-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2011-0032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30705732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

In vitro effects of three antidepressant drugs on plasma paraoxonase activity. 三种抗抑郁药物对血浆对氧磷酶活性的体外影响。

Drug Metabolism and Drug Interactions Pub Date : 2012-01-01 DOI: 10.1515/dmdi-2012-0015

Mohamed Hachem Saadaoui, Ilhem Hellara, Fadoua Neffati, Anouar Mechri, Wahiba Douki, Lotfi Gaha, Mohamed Fadhel Najjar

{"title":"In vitro effects of three antidepressant drugs on plasma paraoxonase activity.","authors":"Mohamed Hachem Saadaoui, Ilhem Hellara, Fadoua Neffati, Anouar Mechri, Wahiba Douki, Lotfi Gaha, Mohamed Fadhel Najjar","doi":"10.1515/dmdi-2012-0015","DOIUrl":"https://doi.org/10.1515/dmdi-2012-0015","url":null,"abstract":"Background: Paraoxonase 1 (PON1) is important in organophosphates and xenobiotic metabolism and as an antioxidant bio-scavenger. PON1 activity was shown to significantly decrease in depressed patients after antidepressant treatment instauration. Our aim was to investigate the in vitro inhibitory effects of three antidepressants (imipramine, amitriptyline and fluoxetine) on PON1 activity.Methods: Plasma from healthy volunteers was spiked with antidepressant drugs. The working solutions were then diluted with plasma to obtain concentrations that covered the therapeutic margin. PON1 was tested by a kinetic method in triplicate after incubation at 37°C for 2 h.Results: Tricyclic antidepressants significantly inhibited PON1. Fluoxetine had no effect. The inhibition percentage for imipramine was 15.6% at 100 μg/L after incubation for 1 h (131±1 vs. 155±2 IU/L; p<0.01). At 350 μg/L, the inhibition percentage for imipramine 19.2% after 1 h and 20.2% after 2 h. Amitriptyline was a stronger inhibitor: 26% after 30 min at 125 μg/L. At 250 μg/L, the inhibition percentage for amitriptyline was 36.5% after 30 min (100±4 vs. 159±2 IU/L; p<0.01).Conclusions: The tested tricyclic antidepressants significantly inhibit PON1 activity in a concentration-dependent manner. Amitriptyline had a higher inhibition potency than imipramine.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 4","pages":"209-15"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2012-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30924697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review. 雷替格拉韦与人参相互作用引起的肝酶升高:一个病例报告和简要回顾。

Drug Metabolism and Drug Interactions Pub Date : 2012-01-01 DOI: 10.1515/dmdi-2012-0019

Héctor Mateo-Carrasco, María C Gálvez-Contreras, Francisco D Fernández-Ginés, Timothy V Nguyen

{"title":"Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review.","authors":"Héctor Mateo-Carrasco, María C Gálvez-Contreras, Francisco D Fernández-Ginés, Timothy V Nguyen","doi":"10.1515/dmdi-2012-0019","DOIUrl":"https://doi.org/10.1515/dmdi-2012-0019","url":null,"abstract":"Background: In the last decade, some evidence has arisen supporting the usefulness of Asian ginseng (Panax ginseng, fam. Araliaceae) as a complementary remedy in patients receiving antiretroviral therapy. However, its role in current therapeutics remains unclear.Methods: The patient was admitted for an acute elevation of liver enzymes, marked jaundice, and significant weight loss after taking ginseng-based tablets starting approximately 39 days prior. His past medical history (PMH) was also significant for HIV+, long-term hepatitis C, an episode of mitochondrial toxicity, and several comorbidities. His outpatient medications included raltegravir 400 mg plus lopinavir/ritonavir 400/100 mg twice daily, aspirin 100 mg daily, and esomeprazole 40 mg daily as needed.Results: The cessation of the ginseng lozenges led to a progressive improvement in the performance status and laboratory values. Both the Hansten and Horn nomogram and the Roussel Uclaf Causality Assessment Method indicated that the association between the ginseng medicine and the liver injury was probable (six points).Conclusions: We suggest that ginseng is involved in the episode through an interaction resulting in elevated plasma concentrations of raltegravir. As a consequence, clinicians should be alert when managing patients on other CYP3A4-metabolized drugs or previous liver-damaging conditions. However, larger studies are required to explicitly clarify these statements.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 3","pages":"171-5"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2012-0019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30997699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

In silico pharmacology for a multidisciplinary drug discovery process. 用于多学科药物发现过程的计算机药理学。

Drug Metabolism and Drug Interactions Pub Date : 2012-01-01 DOI: 10.1515/dmdi-2012-0021

Santiago Schiaffino Ortega, Luisa Carlota López Cara, María Kimatrai Salvador

引用次数: 34

Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders. 拉丁美洲人群的药物遗传学:管制方面，对草药、心血管和精神疾病的应用。

Drug Metabolism and Drug Interactions Pub Date : 2012-01-01 DOI: 10.1515/dmdi-2012-0006

Idania Rodeiro, Diadelis Remírez-Figueredo, Milagros García-Mesa, Pedro Dorado, Adrián LLerena

{"title":"Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.","authors":"Idania Rodeiro, Diadelis Remírez-Figueredo, Milagros García-Mesa, Pedro Dorado, Adrián LLerena","doi":"10.1515/dmdi-2012-0006","DOIUrl":"https://doi.org/10.1515/dmdi-2012-0006","url":null,"abstract":"Meeting report of the \"Second Symposium on Pharmacology of Cytochrome P450 and Transporters\" organized by the Cuban Society of Pharmacology in collaboration with the European Society of Pharmacogenetics and Theranostics (ESPT) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (www.ribef.com). The Symposium covered different topics on pharmacogenetics and its clinical implications, focusing on Latin-American populations. The activities of the ESPT were also presented and discussed. The topics addressed were regulatory aspects, the use of pharmacogenetics in pre-clinical research, herbal medicine, and natural products, ending with a discussion about translation into clinical practice, specifically for cardiovascular disorders and psychiatry. Finally, the implication for population diversity in Latin America was also discussed. The RIBEF initiative represents a promising step towards the inclusion of Latin American populations among those to benefit from the implementation of pharmacogenetics in clinical practice. Among current RIBEF activities, the CEIBA.FP Consortium aims to study the variability of pheno- and genotypes in Hispanics that are relevant to pharmacogenetics. For this purpose, populations from Mexico, Cuba, Nicaragua, Costa Rica, Ecuador, Colombia, Brasil, Perú, Chile, Uruguay, Argentina, Portugal, and Spain are currently being studied. The meeting's main conclusion was that population pharmacogenetic studies as well as academic clinical trials might need to be conducted in the different geographic locations/countries. This is important in order to improve drug safety, dosage recommendations, and pharmacovigilance programs, because environmental and ethnic factors vary across locations.","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"27 1","pages":"57-60"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2012-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30705736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30